Sign In
Buy ACAD
$25.50
-0.720 (-2.75%)
At Close: Jul 13, 2026
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?
04:50pm, Saturday, 11'th Jul 2026
Principal Accounting Officer James Kihara sold 11,421 shares for a transaction value of approximately ~$298,000 on June 26, 2026. The sale represented 46.60% of Kihara's direct holdings and reduced di
RPRX or ACAD: Which Is the Better Value Stock Right Now?
12:40pm, Thursday, 09'th Jul 2026
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD). But which of these two companies is the bes
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
09:04am, Monday, 06'th Jul 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company's global
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
12:16pm, Monday, 29'th Jun 2026
Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus
11:19am, Monday, 29'th Jun 2026
Acadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by a recent positive CHMP opinion for Daybue in Europe. Remlifanserin's upcoming phase 2 readout in Alz
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?
10:40am, Monday, 29'th Jun 2026
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy
01:47pm, Friday, 26'th Jun 2026
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares are trading higher on Friday as the company is celebrating a positive recommendation from the European Medicines Agency Committee for Medicinal Product
Why Acadia Pharmaceuticals Stock Is Soaring Today
12:17pm, Friday, 26'th Jun 2026
Acadia Pharmaceuticals focuses on underserved rare diseases. Although they're (by definition) small markets, there's often little to no competition to treat rare and underserved diseases.
The Surprising Reversal That Drove Acadia Pharma Closer To A Breakout
10:24am, Friday, 26'th Jun 2026
Acadia stock popped Friday after European regulators unexpectedly said they would recommend approval of the Rett syndrome drug, Daybu.
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
06:49am, Friday, 26'th Jun 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted
Acadia (ACAD) Down 3.7% Since Last Earnings Report: Can It Rebound?
12:36pm, Friday, 05'th Jun 2026
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
ACADIA Pharmaceuticals Spotlights Alzheimer's Psychosis Pipeline, NUPLAZID and DAYBUE Growth
10:15am, Tuesday, 19'th May 2026
ACADIA Pharmaceuticals NASDAQ: ACAD executives used an RBC Capital Markets investor session to outline the company's clinical rationale for remlifanserin in Alzheimer's disease psychosis, provide upda
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10:10pm, Tuesday, 12'th May 2026
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
08:25pm, Tuesday, 12'th May 2026
ACADIA Pharmaceuticals NASDAQ: ACAD executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, acco
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
12:46pm, Thursday, 07'th May 2026
Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.
